bluebird, BMS hit roadblock as FDA delivers refuse-to-file letter for myeloma CAR-T
The FDA requested supplemental documentation related to chemistry, manufacturing and controls rather than new clinical or preclinical data. The companies plan to resubmit the application and request a priority review by the end of July.